Canaccord Genuity Group Has Lowered Expectations for Enovis (NYSE:ENOV) Stock Price

Enovis (NYSE:ENOV) had its price target cut by equities research analysts at Canaccord Genuity Group from $45.00 to $42.00 in a note issued to investors on Friday, Benzinga reports. The firm currently has a “buy” rating on the stock. Canaccord Genuity Group‘s price objective suggests a potential upside of 53.83% from the stock’s previous close.

ENOV has been the subject of a number of other research reports. Wells Fargo & Company raised their price target on Enovis from $33.00 to $37.00 and gave the stock an “overweight” rating in a research note on Friday. Needham & Company LLC increased their target price on Enovis from $34.00 to $38.00 and gave the stock a “buy” rating in a research note on Thursday. UBS Group restated a “buy” rating and set a $44.00 price target on shares of Enovis in a report on Monday, October 5th. Zacks Research raised shares of Enovis from a “strong sell” rating to a “hold” rating in a research report on Wednesday, July 29th. Finally, Citizens Jmp lowered their price target on Enovis from $55.00 to $47.00 and set a “market outperform” rating on the stock in a report on Wednesday, September 2nd. Ten research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $38.62.

Enovis Price Performance

Shares of ENOV stock traded down $1.32 on Friday, reaching $27.30. The company’s stock had a trading volume of 831,913 shares, compared to its average volume of 1,267,764. The stock’s 50 day simple moving average is $19.86 and its 200-day simple moving average is $23.07. The company has a market capitalization of $1.57 billion, a P/E ratio of -1.43 and a beta of 1.31. The company has a quick ratio of 1.00, a current ratio of 1.98 and a debt-to-equity ratio of 0.84. Enovis has a 12-month low of $16.70 and a 12-month high of $32.41.

Enovis (NYSE:ENOV) last issued its quarterly earnings results on Thursday, November 5th. The company reported $0.88 EPS for the quarter, beating analysts’ consensus estimates of $0.77 by $0.11. Enovis had a negative net margin of 47.96% and a positive return on equity of 12.03%. The business had revenue of $558.73 million for the quarter, compared to analysts’ expectations of $557.12 million. During the same period last year, the business earned $0.75 earnings per share. The business’s quarterly revenue was up 1.8% on a year-over-year basis. As a group, equities analysts predict that Enovis will post 3.15 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other news, insider Oliver Engert acquired 5,140 shares of Enovis stock in a transaction that occurred on Thursday, September 3rd. The stock was bought at an average price of $19.46 per share, for a total transaction of $100,024.40. Following the completion of the transaction, the insider owned 61,238 shares in the company, valued at $1,191,691.48. The trade was a 9.16% increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Damien Mcdonald bought 13,035 shares of the stock in a transaction on Friday, September 4th. The stock was purchased at an average cost of $19.15 per share, for a total transaction of $249,620.25. Following the acquisition, the chief executive officer owned 247,077 shares of the company’s stock, valued at $4,731,524.55. This trade represents a 5.57% increase in their position. The SEC filing for this purchase provides additional information. Over the last 90 days, insiders bought 23,293 shares of company stock worth $449,599. Company insiders own 2.90% of the company’s stock.

Institutional Investors Weigh In On Enovis

Several hedge funds and other institutional investors have recently made changes to their positions in ENOV. Maryland State Retirement & Pension System purchased a new position in shares of Enovis in the third quarter worth approximately $238,000. Illinois Municipal Retirement Fund grew its position in Enovis by 22.4% during the third quarter. Illinois Municipal Retirement Fund now owns 38,366 shares of the company’s stock valued at $701,000 after buying an additional 7,028 shares during the period. Private Management Group Inc. increased its holdings in Enovis by 31.3% during the third quarter. Private Management Group Inc. now owns 1,792,429 shares of the company’s stock valued at $32,748,000 after buying an additional 427,347 shares during the last quarter. Fulcrum Asset Management LLP increased its holdings in Enovis by 2,739.4% during the third quarter. Fulcrum Asset Management LLP now owns 20,330 shares of the company’s stock valued at $375,000 after buying an additional 19,614 shares during the last quarter. Finally, Villanova Investment Management Co increased its holdings in Enovis by 10.2% during the third quarter. Villanova Investment Management Co now owns 148,424 shares of the company’s stock valued at $2,712,000 after buying an additional 13,740 shares during the last quarter. Hedge funds and other institutional investors own 98.45% of the company’s stock.

Enovis News Roundup

Here are the key news stories impacting Enovis this week:

• Positive Sentiment: Q3 earnings beat estimates: Enovis reported adjusted earnings of $0.88 per share, above the $0.77 consensus and up from $0.75 a year earlier. Revenue of $558.7 million edged past expectations and rose 1.8% year over year. Enovis Q3 2026 results
• Positive Sentiment: Higher outlook and buyback: The company raised its 2026 EPS guidance to $3.58–$3.79 and authorized a $200 million share repurchase program. The higher forecast signals improved earnings expectations; repurchases may also support per-share results. Guidance and buyback announcement
• Positive Sentiment: Analysts lifted price targets: Wells Fargo raised its target to $37 and kept an Overweight rating; Needham raised its target to $38 with a Buy rating, and BTIG raised its target to $42 with a Buy rating. These revisions reflect more optimistic analyst views following the results. Wells Fargo ratings
• Neutral Sentiment: Despite these positive updates, ENOV was lower in the supplied trading snapshot. The available reports do not cite a specific negative development explaining the weakness.

Enovis Company Profile

Enovis Corporation (NYSE: ENOV) is a medical technology company that develops, manufactures and distributes products designed to improve patient recovery, mobility and quality of life. Its portfolio serves orthopedic, sports medicine, physical therapy and rehabilitation markets, as well as other areas of musculoskeletal care.

The company’s products include orthopedic implants and surgical technologies, braces and supports, cold and compression therapy systems, electrotherapy and rehabilitation equipment, and other solutions used by hospitals, surgeons, physical therapists, athletic trainers and patients.